Chimerix tanks, SEC probes Anavex and KaloBios staggers into bankruptcy

What did you miss during the Christmas break? The short answer: Not much. The last week of the year is usually highlighted by a few last-minute deals that need to be reported ahead of New Year's day. But evidently any big deals in the offing have been reserved for the lead-up to JP Morgan. The news in biotech centered around a few key setbacks and a cleanup on aisle Shkreli. We reported that Chimerix's ($CMRX) lead therapy failed a key Phase III study, which sent its shares into meltdown mode. KaloBios is back on the brink after Martin Shkreli's disastrous rescue attempt, filing for bankruptcy protection. And the small Alzheimer's player Anavex revealed that the SEC is investigating the company, apparently focusing on suspicious trading activity involving their shares.

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.